Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.
Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.
复制标题
DOI:
10.1007/s40268-017-0215-7
复制
发表时间:
2017-12
期刊:
影响因子:
3
通讯作者:
Caso F
中科院分区:
文献类型:
--
作者:
Costa L;Perricone C;Chimenti MS;Del Puente A;Caso P;Peluso R;Bottiglieri P;Scarpa R;Caso F
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy. Therapy with anti-tumor necrosis factor (TNF)-α agents represents the first therapeutic choice for moderate and severe forms; however, PsA patients can experience anti-TNFα failure, lack of efficacy, or adverse events. Several evidences exist on the effectiveness of switching among different TNFα inhibitors, and we reviewed the published data on the effectiveness of anti-TNFα first-, second- and third-line. Most of the studies report that the main reason for switching to a second anti-TNFα agent is represented by lack of efficacy (primary or secondary) and, more rarely, adverse events. Switchers receiving their second anti-TNFα agent have considerably poorer responses compared with non-switchers. Survival of anti-TNFα treatment appears to be superior in PsA patients when compared with rheumatoid arthritis patients. Switching from anti-TNF agents to ustekinumab or secukinumab or apremilast can represent a valid alternative therapeutic strategy.
登录
查看更多内容
影响因子:
3.8
作者:
Chastek, Benjamin;Fox, Kathleen M.;Gandra, Shravanthi R.
通讯作者:
Gandra, Shravanthi R.
影响因子:
4.4
作者:
Costa, Luisa;Caso, Francesco;Scarpa, Raffaele
通讯作者:
Scarpa, Raffaele
DOI:
10.3109/09546634.2012.755255
发表时间:
2013-10
期刊:
The Journal of dermatological treatment
影响因子:
--
作者:
Bonafede M;Johnson BH;Fox KM;Watson C;Gandra SR
通讯作者:
Gandra SR
影响因子:
--
作者:
Arstikyte, Inesa;Kapleryte, Giedre;Venalis, Algirdas
通讯作者:
Venalis, Algirdas
影响因子:
4.6
作者:
Caso F;Costa L;Rigante D;Lucherini OM;Caso P;Bascherini V;Frediani B;Cimaz R;Marrani E;Nieves-Martín L;Atteno M;Raffaele CG;Tarantino G;Galeazzi M;Punzi L;Cantarini L
通讯作者:
Cantarini L